Clinical Trials Browser

Phase 3 × 130-nm albumin-bound paclitaxel × 30 days × Clear all

NCT06096844 2026-06-03

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Phase 3 Recruiting

Lung Neoplasms

NCT07491445 2026-06-03

RASolute 303

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06018337 2026-06-02

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Phase 3 Active not recruiting

Breast Neoplasms

NCT06608927 2026-06-02

PRISM-1

Phase 3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06625320 2026-06-02

RASolute 302

Phase 3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07621718 2026-06-02

RASolute 305

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06422143 2026-06-01

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06841354 2026-05-29

TroFuse-011

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03520686 2026-05-26

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT06312176 2026-05-22

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07173751 2026-05-22

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT04768075 2026-05-20

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

644 enrolled 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04251533 2026-05-11

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT06279364 2026-05-08

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT07071337 2026-05-08

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Phase 3 Recruiting

Breast Neoplasms